[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bioaraba Health Research Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":64},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100461906",false,"NCT05294744","Utility of the Use of N-acetylcysteine Associated With Conventional Treatment in Patients With Severe Acute Alcoholic Hepatitis (Maddrey> 32)","Inclusion Criteria:\n\n* Men and women.\n* Age from 18 to 75 years.\n* Patients with acute alcoholic hepatitis according to AASLD criteria or compatible liver histology.\n* Maddrey score\\> = 32.\n* Acceptance of participation through written informed consent.\n\nExclusion Criteria:\n\n* Any cause of jaundice: acute hepatitis, positive HIV serology, biliary-pancreatic pathology, hemolytic anemia.\n* Allergy or intolerance to N-acetylcysteine and \u002F or corticosteroids.\n* Hepatocarcinoma.\n* Portal cavernomatosis.\n* Portal cavernomatosis.\n* Any disease whose life expectancy is less than 12 months.\n* Patients with nitroglycerin and \u002F or carbamazepine-based treatments.\n* Patients with uncontrolled active infection.\n* Acute kidney disease with creatinine\\> 2.5 mg \u002F dL.\n* Uncontrolled upper gastrointestinal bleeding.\n* Concomitant uncontrolled diseases (HBV, HCV, HIV, TB, DILI, HCC or acute pancreatitis).\n* Multiple organ failure or shock.","ALL","18 Years","75 Years",{"count":18,"type":19},390,"ESTIMATED","INTERVENTIONAL",[22],"NA","This study is designed to evaluate the hypothesis that patients with severe acute alcoholic hepatitis have lower morbi-mortality if the patients receive treatment with corticosteroids + NAC, compared to patients that only receive corticosteroids.",[25],"Alcoholic Hepatitis","RECRUITING","2026-01-08",{"date":29,"type":30},"2026-01-12","ACTUAL",{"date":32,"type":30},"2022-10-07",{"date":34,"type":19},"2026-12",{"name":36,"class":37},"Bioaraba Health Research Institute","NETWORK",1,{"id":40,"slug":4,"hasResults":10,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":10,"sex":14,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":20,"phases":49,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":38},"100579167","NCT06820775","EFFECTIVENESS OF A TRIPLE NUTRITIONAL INTERVENTION AND PHYSICAL IN PREDIABETIC PATIENRS","EFFECTIVENESS OF A TRIPLE NUTRITIONAL INTERVENTION AND PHYSICAL ACTIVITY FOR GLYCOSYLATED HB CONTROL IN PREDIABETICS: CLINICAL TRIAL","Inclusion Criteria:\n\nPrediabetics with glycosylated hemoglobin (HbA1c) 5.7-6.4 (24, 38) and signing informed consent.\n\n\\-\n\nExclusion Criteria:\n\nPresence of physical or psychological illnesses that prevent physical activity; participation in another research project; pregnancy or breastfeeding; patients undergoing dietary or pharmacological treatment for weight loss; history of myocardial infarction or stroke; diabetic, taking drugs for diabetes mellitus and taking drugs such as Gliflozin for pathologies other than diabetes mellitus.\n\nof physical or psychological illnesses that prevent physical activity; participation in another research project; pregnancy or breastfeeding; patients undergoing dietary or pharmacological treatment for weight loss; history of myocardial infarction or stroke; diabetic, taking drugs for diabetes mellitus and taking drugs such as Gliflozin for pathologies other than diabetes mellitus.","35 Years","70 Years",{"count":48,"type":19},82,[22],"Diabetes represents a substantial burden on health care systems. People with prediabetes IGT (impaired glucose tolerance) or IFG (impaired fasting glucose) are at high risk of developing diabetes, and up to 50% progress to diabetes within 5 years.\n\nOBJECTIVE: To evaluate the effectiveness of a triple intervention (physical activity and ordered healthy diet) to improve glycosylated hemoglobin control in prediabetic patients.\n\nMATERIAL AND METHODOLOGY: Randomized, open, controlled clinical trial with routine clinical practice (health advice for physical activity and healthy diet). Study population: obese or overweight patients of the OSI Araba aged 35-70 years who are in the contemplation stage.\n\nResponse assessment: Primary variable: glycosylated hemoglobin; Secondary variables: Body Mass Index (BMI) (kg\u002Fcm2); blood pressure (mm Hg); satisfaction questionnaire score; physical exercise index (IPAQ) (METs). Statistical analysis: The analysis of the main variable (change in HbA1c at 6 months between both groups) will be assessed by analysis of covariance, ANCOVA, adjusting for baseline HbA1c. Sample size: 41 patients per arm (+30% to cover losses to follow-up).",[52],"Diabetes",[54],"DIABETES MELLITUS","NOT_YET_RECRUITING","2025-02-10",{"date":58,"type":30},"2025-02-11",{"date":60,"type":19},"2025-02-02",{"date":62,"type":19},"2025-06-30",{"name":36,"class":37},""]